Ash Stevens a provider of global contract pharmaceutical chemical development and API (Active Pharmaceutical Ingredient) manufacturing services, has announced that the U.S Food and Drug Administration (FDA) has approved ASI's facility in Riverview, Michigan for the manufacture of the API ixazomib, an oral proteasome inhibitor indicated in combination with leanlidomide and dexamethasone for the treatment of patients multiple myeloma who have received at least one prior therapy.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.